Effect of zinc therapy on natural killer cell activity in inflammatory bowel disease.

What Was Tested

Researchers studied Zinc in this randomized controlled trial publication.

Disturbances in zinc metabolism have been documented in patients with inflammatory bowel disease.

In this study the researchers evaluated the effect of in vivo treatment with zinc on the in vitro natural killer cell activity in thirteen inflammatory bowel disease patients, with stable disease and mild-moderate disease activity, in a double-blind randomized cross-over trial.

Who Took Part

By PubMed's age tags, the people studied were adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and crossover.

Because people in this Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Zinc.

Each person switched between Zinc and the comparison at some point, usually with a gap in between.

What Was Measured

In this study the researchers evaluated the effect of in vivo treatment with zinc on the in vitro natural killer cell activity in thirteen inflammatory bowel disease patients, with stable disease and mild-moderate disease activity, in a double-blind randomized cross-over trial.

PubMed files the paper under topics including Cell Survival, Colitis, Ulcerative, Crohn Disease, Diet, Inflammatory Bowel Diseases, Killer Cells, Natural and Zinc.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Zinc.

The publication is from 1993 (Alimentary pharmacology & therapeutics), a journal based in England.

More context: the related Vitamin D, K2, Magnesium and Zinc library page, all human trials.